Blurred near vision due to mydriasis. Therefore these drugs are contraindicated in narrow-angle glaucoma. This is a mild antiparkinsonian drug . The dose should be reduced with renal impairment. However, there has been considerable controversy over the interpretation of the results of this and other studies in that was Selegiline truly neuroprotective or does it have some kind of symptomatic effect.
Most neurologists now tend to favour the latter.
This has been shown in one study, however, the causes of death are unknown at present. Nonetheless it would seem to lay to rest the neuroprotective argument for Selegiline. Since we do not have data from any other studies or details on the causes of death in the Selegiline group in the BMJ paper, at present we do not know whether the reported increased mortality in the BMJ paper is causally linked with Selegiline or not. Sinemet, Madopar Since dopamine does not cross the blood brain barrier, but its precursor Levodopa does, L-Dopa is given in an effort to replace the striatal dopamine deficiency. These probably represent the biggest single problem in the long-term management of a patient with Parkinson's disease.